RecruitingPhase 1NCT06564987

Risk of Nerve Damage After Administration of Local Anesthesia

Risk of Nerve Damage After Administration of an Inferior Alveolar Nerve Block Using 4% Articaine Versus 2% Lidocaine


Sponsor

Cleveland Dental Institute

Enrollment

80 participants

Start Date

Jan 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This research aims to evaluate of the risk of nerve damage following the administration of articaine 4% and lidocaine 2% for Inferior Alveolar nerve Block (IANB). A Randomized Controlled Clinical Trial will be conducted where the patient will be randomly assigned to one the two groups; articaine 4% and Lidocaine 2%. The type of LA will be concealed to the operator, investigators and assessors. The patients will be monitored for any aigns of nerve parathesia for 3 months after the procedure.


Eligibility

Min Age: 18 YearsMax Age: 55 Years

Inclusion Criteria3

  • Patients with age between 18-55 years old
  • Patients need IANB
  • healthy patient

Exclusion Criteria6

  • medical conditions
  • allergies
  • medications
  • pregnancy and breastfeeding
  • inability to provide informed consent
  • specific dental or medical history.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG4% Articaine with 1:200,000 epinephrine

Inferior Alveolar Nerve Block with 4% articaine

DRUG2% lidocaine with 1:100,000 epinephrine

Inferior Alveolar Nerve Block with 2% lidocaine


Locations(2)

Cleveland Dental Institute

Akron, Ohio, United States

Cleveland Dental Institute

Ashtabula, Ohio, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06564987


Related Trials